- Fordham B.A.The role of Mindfulness based cognitive therapy in the management of
Psoriasis, the university of Manchester. (2012). 116-119.
2. Bundy C, Pinder B, Bucci S, Reeves D, Griffiths C.E.M, Tarrier N. A novel, web‐based,
psychological intervention for people with psoriasis: the electronic Targeted Intervention for
Psoriasis (e TIP s) study. Br J Dermatol. 2013;169(2):329-36.
3. Kim H.J. & Lebwohl M.G. Biologics and Psoriasis the Beat Goes on. Dermatologic Clinics.
2019; 37(1):29-36.
4. Sarafino E. Psycology of Health, Translating Elahe Mirzaee et al., Tehran: Growth
Publication. 2008.
5.Al-Mutairi N, Al-Faraq S, Al-Mutairi A, Al-Shiltawy M. Comorbidities associated with
psoriasis: an experience from the Middle East. J Dermatol 2010; 37: 146–155.
- 6.Rosenstock I.M. The health belief model: explaining health behavior through
expectancies.1990.
7. Naldi L., Chatenoud L., Linder D., Belloni F. A., Peserico A., Virgili A. R., et al. Cigarette
smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an
Italian case–control study. J Invest Dermatol. 2005; 125(1):61-7.
8. Rigopoulos D, Gregoriou S, Katrinaki A, Korfitis C., Larios G., Stamou C., et al.
Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny
Mediterranean climate. Eur J Dermatol. 2010 ;1;20(2):189-95.
9.Ghajarzadeh M, Kheirkhah S, Ghyiasi M. Quality of life and depression in patients with
vitiligo. jdc. 2011; 2 (4) :203-209
10. Barrea L., Nappi F., Di Somma C., Savanelli M. C., Falco A., Balato A., et al. Environmental
risk factors in psoriasis: the point of view of the nutritionist. Int J Environ Res Public Health.
2016; 22;13(7):743
11. Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities.
An Bras Dermatol 2015; 90: 9–20.
12. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., et al.
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines
of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and
evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137–174
13.Nast A., Gisondi P., Ormerod A.D., Splus P.I., Gisondi P., Paul C., et al. European S3-
Guidelines on the systemic treatment of psoriasis vulgaris–Update 2015–Short version–EDF in
cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015; 29: 2277–2294.
14.Mrowietz U., Barker J., Boehncke W.H., Iversen L., Kirby B., Naldi L., et al. Clinical use of
dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J
Eur Acad Dermatol Venereol 2018; 32(Suppl 3): 3–14.
15.Mrowietz U, Szepietowski JC, Loewe R., Van de Kerkhof P., Lamarca R., Ocker W.G., et al.
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic
plaque psoriasis: a randomized, double-blind, Fumaderm(R) - and placebo-controlled trial
(BRIDGE). Br J Dermatol 2017; 176: 615–623.
16.European Medicines Agency (EMA). EPAR summary for the public: Skilarence, dimethyl
fumarate. URL
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Summary_for_the_public/hu
man/ 002157/WC500231110.pdf (last accessed: 2017 July 2018).
17.Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;
64(Suppl 2): ii65–ii68; discussion ii69-73.
18. Oji V, Luger TA. The skin in psoriasis: assessment and challenges. Clin Exp Rheumatol
2015; 33: S14–S19.
19.Feldman S.R., Fleischer A.B., Reboussin D.M., Bradham D.D., Exum M.L., Clark A.R. The
economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol 1997; 37:
564–569.
20. Gelfand J.M., Feldman S.R., Stern R.S., Thomas J., Rolstad T., Margolis D.J. Determinants
of quality of life in patients with psoriasis: a study from the US population. J Am Acad of
Dermatol. 2004; 51(5):704-708.
21. Mohammad Khanei P., Khannipour H. Mind-focused treatments. Tehran: Publications of
University of Welfare. 2012.
22. Fortune D.G., Richards H.L., Kirby B., Bowcock S., Main C.J. & Griffiths C.E. A
cognitive‐behavioural symptom management programme as an adjunct in psoriasis therapy. Br J
Dermatol. 2002;146(3):458-65.
23.Kwon C.W., Fried R.G., Nousari Y., Ritchlin C. & Tausk F. Psoriasis: Psychosomatic,
somatopsychic, or both? Clin Dermatol 2018; 36(6): 698-703.
24.Dahlgaard J., Jørgensen M.M., Velden A.M., Sumbundu A., Gregersen N., Olsen R.K.,et al.
Mindfulness, health, and longevity. In the science of hormesis in health and longevity. Academic
Press 2019; 243-55. 19.
25.Ivtzan I., Young T., Martman J., Jeffrey A., Lomas T., Hart R., et al. Integrating mindfulness
into positive psychology: A randomised controlled trial of an online positive mindfulness
program. Mindfulness 2016; 7(6): 1396-1407. 20.
26.Kashdan T.B., Ciarrochi J.V., editors. Mindfulness, acceptance, and positive psychology: The
seven foundations of well-being. New Harbinger Publications. 2013.
27. Williams J.M., Duggan D.S., Crane C. & Fennell M.J. Mindfulness‐Based cognitive therapy
for prevention of recurrence of suicidal behavior. J clin psychol. 2006;62(2):201-10.
28.Gaylord S.A., Palsson O.S., Garland E.L., Faurot K.R., Coble R.S., Mann J.D., et al.
Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a
randomized controlled trial. Am J Gastroenterol. 2011;106(9):1678.
29. Alibeige-Beni E., Salehi A. & Jafary F. The Effect of Mindfulness-Based Stress Reduction
Program on Emotional WellBeing (Stress, Anxiety, Depression, and Sadness) of Patients with
Psoriasis. Journal of Isfahan Medical School.21735(436):756-762.
30.Greeson J.M., Smoski M.J. & Suarez E.C., Brantley J.G., Ekblad A.G., Lynch T.R, et al.
Decreased symptoms of depression after mindfulness-based stress reduction: potential
moderating effects of religiosity, spirituality, trait mindfulness, sex, and age. J Altern
Complement Med. 2015;21(3):166-74.
31.Kaviani H., Javaheri F. & Bahraini H. The effectiveness of cognitive-based cognitive therapy
is to reduce their thoughts. Negative, ineffective attitude, depression and anxiety follow-up 60
days. Journal of Cognitive Sciences, (2005). 1 (7): 58-49.
32. Villasenor-Park Jennifer, Wheeler David, Grandinetti Lisa, "Psoriasis: Evolving treatment
for a complex disease “. Cleveland Clinic Journal of Medicine, 2012; 79 (6):413-423.
33. Segal ZV, Williams JMG. & Teasdale JD. Mindfulness-Based Cognitive therapy for
depression: A new approach to preventing relapse New York: Guilford Press. (2002).
34. Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc
Behav. 1983; 1:385-96.
35.Bastani F., Rahmatnejad L., Jesmi F., Haghani H. Breastfeeding Self efficacy and Perceived
Stress. Iranian Journal of Nursing. 2008.21(54). pp:9-22.
36. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)—a simple practical measure
for routine clinical use. Clinical and experimental dermatology. 1994;19(3):210-6.
37. Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability
and validity of the Persian version. BMC dermatol. 2004;4(1):8.
38. Sohrabi F., Jaffari Fard S., Zareei S. & Eskandari H. The effectiveness of mindfulness based
cognitive therapy on panic disorder. Journal of Clinical Psychology. 2013.4(16):31-43.
39. Smits J.A., Minhajuddin A., Jarrett R.B. Cognitive therapy for depressed adults with
comorbid social phobia. J Affect Disord. 2009;114(1-3):271-8.
40. Grossman P., Niemann L., Schmidt S. & Walach H. Mindfulness-based stress reduction and
health benefits: A meta-analysis. J Psychosom Res. 2004 Jul 1;57(1):35-43.
- 41.Kabat-Zinn J. Mindfulness‐based interventions in context: past, present, and future. Clinical
psychology: Science and practice. 2003;10(2):144-56.
|
